Prix Nanjing Leads Biolabs Co Ltd (09887.HK)

Nanjing Leads Biolabs Co., Ltd. operates as a pharmaceutical company. The company is headquartered in Nanjing, Jiangsu and currently employs 192 full-time employees. The company went IPO on 2025-07-25. The Company’s main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007 and others. The firm's LBL-024 is mainly used to treat extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC) and other solid tumors. The firm has also developed multiple proprietary technology platforms, including LeadsBod platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform) and several other bispecific antibody and fusion protein platforms. The firm mainly conducts its business in the domestic market.